Seven CHD candidate genes, including EGFR, EVC2, NFATC2, NR2F2, TBX5, CFC1B and GJA5, were chosen for further validation in a larger number of TOF cases because of their nominally significant differences in methylation levels and the important roles they play in the development of the heart. This evidence concerns the gene NFATC2 and coronary artery disorder.